{"DataElement":{"publicId":"2503547","version":"1","preferredName":"Prior Curative Systemic Therapy Administered Type","preferredDefinition":"the type of prior treatment intended to cure using substances that travel through the bloodstream, reaching and affecting cells all over the body.","longName":"P_CUR_SYSTX_ADM_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2503544","version":"1","preferredName":"Prior Curative Systemic Therapy Administered","preferredDefinition":"information related receiving prior treatment intended to cure using substances that travel through the bloodstream, reaching and affecting cells all over the body.","longName":"PRIOR_CUR_SYSTX_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2503542","version":"1","preferredName":"Prior Curative treatment Systemic Therapy","preferredDefinition":"Earlier in time or order.:No value exists.:(sis-TEM-ik THER-a-pee) Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","longName":"C25629:CL282358:C15698","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior","conceptCode":"C25629","definition":"Earlier in time or order.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Curative treatment","conceptCode":"CL282358","definition":"No value exists.","evsSource":"NCI_META_CUI","primaryIndicator":"No","displayOrder":"1"},{"longName":"Systemic Therapy","conceptCode":"C15698","definition":"Treatment using substances that travel through the bloodstream, reaching and affecting cells all over the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A20331D-0D92-38D2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-03","modifiedBy":"ONEDATA","dateModified":"2006-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A20331D-0DA0-38D2-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2503545","version":"1","preferredName":"Prior Systemic Therapy Type","preferredDefinition":"the type of previous therapy that is given throughout the entire body.","longName":"PR_SYSTX_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Cisplatin","valueDescription":"Cisplatin","ValueMeaning":{"publicId":"2567154","version":"1","preferredName":"Cisplatin","longName":"2567154","preferredDefinition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D35F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-30","endDate":null,"createdBy":"PFOWLER","dateCreated":"2003-10-30","modifiedBy":"COOPERM","dateModified":"2020-08-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1A20597C-C7C8-40A8-E044-0003BA3F9857","beginDate":"2006-08-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-03","modifiedBy":"ALAIS","dateModified":"2006-08-03","deletedIndicator":"No"},{"value":"Carboplatin","valueDescription":"CBDCA (Carboplatin)","ValueMeaning":{"publicId":"2576636","version":"1","preferredName":"CBDCA (Carboplatin)","longName":"2576636","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F869-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"REEVESD","dateModified":"2012-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1A20597C-C7DD-40A8-E044-0003BA3F9857","beginDate":"2006-08-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-03","modifiedBy":"ALAIS","dateModified":"2006-08-03","deletedIndicator":"No"},{"value":"Fluorouracil","valueDescription":"Fluorouracil","ValueMeaning":{"publicId":"2561703","version":"1","preferredName":"Fluorouracil","longName":"2561703","preferredDefinition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity.  Fluorouracil and its metabolites possess a number of different mechanisms of action.  In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth.  Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), a necessary constituent of DNA.  Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both the processing and functions of RNA. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE14-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"REEVESD","dateModified":"2009-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1A20597C-C7E9-40A8-E044-0003BA3F9857","beginDate":"2006-08-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-03","modifiedBy":"ALAIS","dateModified":"2006-08-03","deletedIndicator":"No"},{"value":"Docetaxel","valueDescription":"Docetaxel","ValueMeaning":{"publicId":"2576637","version":"1","preferredName":"Docetaxel","longName":"2576637","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1A20597C-C7F5-40A8-E044-0003BA3F9857","beginDate":"2006-08-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-03","modifiedBy":"ALAIS","dateModified":"2006-08-03","deletedIndicator":"No"},{"value":"Paclitaxel","valueDescription":"PACLITAXEL","ValueMeaning":{"publicId":"2561015","version":"1","preferredName":"PACLITAXEL","longName":"2561015","preferredDefinition":"PACLITAXEL","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BB64-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-04-11","endDate":null,"createdBy":"JASUR","dateCreated":"2002-04-11","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1A20597C-C801-40A8-E044-0003BA3F9857","beginDate":"2006-08-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-03","modifiedBy":"ALAIS","dateModified":"2006-08-03","deletedIndicator":"No"},{"value":"Cetuximab","valueDescription":"Cetuximab","ValueMeaning":{"publicId":"2574309","version":"1","preferredName":"Cetuximab","longName":"2574309","preferredDefinition":"A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cetuximab","conceptCode":"C1723","definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF52-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1A20597C-C80D-40A8-E044-0003BA3F9857","beginDate":"2006-08-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-03","modifiedBy":"ALAIS","dateModified":"2006-08-03","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1A20597C-C819-40A8-E044-0003BA3F9857","beginDate":"2006-08-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-03","modifiedBy":"ALAIS","dateModified":"2006-08-03","deletedIndicator":"No"},{"value":"Capecitabine","valueDescription":"CAPECITABINE","ValueMeaning":{"publicId":"2561705","version":"1","preferredName":"CAPECITABINE","longName":"2561705v1.00","preferredDefinition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE16-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"CLOHNES","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"202CE3B7-1C0B-3548-E044-0003BA3F9857","beginDate":"2006-10-19","endDate":null,"createdBy":"PWEST","dateCreated":"2006-10-19","modifiedBy":"ONEDATA","dateModified":"2006-10-19","deletedIndicator":"No"},{"value":"Cyclophosphamide","valueDescription":"CYCLOPHOSPHAMIDE","ValueMeaning":{"publicId":"2561009","version":"1","preferredName":"CYCLOPHOSPHAMIDE","longName":"2561009v1.00","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BB5E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-04-11","endDate":null,"createdBy":"JASUR","dateCreated":"2002-04-11","modifiedBy":"KUMMEROA","dateModified":"2023-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"202CE3B7-1C16-3548-E044-0003BA3F9857","beginDate":"2006-10-19","endDate":null,"createdBy":"PWEST","dateCreated":"2006-10-19","modifiedBy":"ONEDATA","dateModified":"2006-10-19","deletedIndicator":"No"},{"value":"Doxorubicin","valueDescription":"Doxorubicin","ValueMeaning":{"publicId":"2561008","version":"1","preferredName":"Doxorubicin","longName":"2561008","preferredDefinition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BB5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-04-11","endDate":null,"createdBy":"JASUR","dateCreated":"2002-04-11","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"202CE3B7-1C21-3548-E044-0003BA3F9857","beginDate":"2006-10-19","endDate":null,"createdBy":"PWEST","dateCreated":"2006-10-19","modifiedBy":"ONEDATA","dateModified":"2006-10-19","deletedIndicator":"No"},{"value":"Trastuzumab","valueDescription":"Trastuzumab","ValueMeaning":{"publicId":"2576422","version":"1","preferredName":"Trastuzumab","longName":"2576422","preferredDefinition":"A humanized recombinant monoclonal antibody directed against the HER2- receptor protein.  Trastuzumab binds to the extracellular domain of the growth factor protein HER2, thereby inhibiting proliferation of HER2 overexpressing tumor cells.  Binding with HER2 protein also initiates an antibody-dependent cell cytotoxicity.(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab","conceptCode":"C1647","definition":"A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F793-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-10-04","modifiedBy":"REEVESD","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"202CE3B7-1C2C-3548-E044-0003BA3F9857","beginDate":"2006-10-19","endDate":null,"createdBy":"PWEST","dateCreated":"2006-10-19","modifiedBy":"ONEDATA","dateModified":"2006-10-19","deletedIndicator":"No"},{"value":"Vinorelbine","valueDescription":"Vinorelbine","ValueMeaning":{"publicId":"2576638","version":"1","preferredName":"Vinorelbine","longName":"2576638","preferredDefinition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle,resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinorelbine","conceptCode":"C1275","definition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"202CE3B7-1C37-3548-E044-0003BA3F9857","beginDate":"2006-10-19","endDate":null,"createdBy":"PWEST","dateCreated":"2006-10-19","modifiedBy":"ONEDATA","dateModified":"2006-10-19","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A205965-B4A9-3D93-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-03","modifiedBy":"COOPERM","dateModified":"2017-08-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Prior systemic therapy (as pa","type":"Preferred Question Text","description":"Prior systemic therapy (as part of curative therapy)","url":null,"context":"CTEP"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1A214F84-9876-061C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-03","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-08-03","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}